"Diabetes Medications Ozempic and Wegovy Offer Heart Protection"
Novo Nordisk's drugs Ozempic and Wegovy, originally developed to treat type 2 diabetes and for weight management, have shown potential in protecting the heart. Recent trials have indicated that semaglutide, the active ingredient in these drugs, may reduce the risk of stroke and heart attack by 20% in people with obesity and a history of cardiovascular disease. The drugs may also have anti-inflammatory effects and dampen alcohol cravings. The findings suggest that semaglutide could have broader cardiovascular benefits and be used in conjunction with statins to further reduce cardiovascular risks. However, accessibility and affordability remain challenges, as the drugs are currently expensive and in limited supply. Novo Nordisk plans to seek regulatory approval for additional uses of semaglutide.
